Huntsman has generated consistent revenue growth, with 4Q:$11.6B,12.2B,12.0B,12.4B in its most recent quarters. Despite the topline growth, Huntsman's net margins have been under pressure, declining from 9.8% in 4Q 2025 to 7.2% in the most recent quarter. The margin compression appears to be driven by a combination of rising input costs and a more challenging pricing environment in certain specialty chemicals markets. However, the data suggests Huntsman has begun to regain pricing power in recent quarters. Huntsman's balance sheet has strengthened, with the debt-to-equity ratio improving from 0.8x a year ago to 0.6x currently. Huntsman's focus on deleveraging and disciplined capital allocation suggests the company is positioning itself for margin recovery and improved return on invested capital (ROIC) over the next 12-18 months. If Huntsman can continue to reduce debt and maintain its revenue growth trajectory, I see potential for the company's net margins to recover towards 10% within the next 2-3 quarters. This, combined with Huntsman's current valuation, could drive the stock price 15-20% higher over the next 6-9 months. Overall, Huntsman's combination of steady top-line growth, balance sheet improvement, and potential for margin expansion makes it an attractive mid-cap specialty chemicals play at the current valuation.

Research these companies